Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-610, 355 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PF-610,355 | DRUG | - |
| Salmeterol | DRUG | - |
Inclusion Criteria: * Reversible asthmatic patients (\>15% increase in FEV1 following 200ug salbutamol). * FEV1 greater than or equal to 60% predicted * Stable disease for at least the previous 3 months Exclusion Criteria: * Subjects requiring rescue medication on greater than 2 occasions in the ...
Top 15 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 5 | PHASE3 | Trelegy Ellipta, Depemokimab, GSK5784283, Ventolin |
| Sanofi SA Sponsored ADR | SNY | 7 | PHASE3 | Dupilumab, Amlitelimab, Lunsekimig |
| AstraZeneca PLC | AZN | 26 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07275315 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
PF-610,355 is an investigational small molecule being studied for the treatment of asthma. It is designed to open the airways in asthmatic patients, according to a completed Phase 2 clinical trial. The drug is being developed by Pfizer, Inc. and is not yet approved for any use.
PF-610,355 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule in Phase 2 clinical development for the treatment of asthma.
PF-610,355 is in Phase 2 clinical development. A Phase 2 trial has been completed, but the drug remains investigational and has not been approved by regulatory authorities. It is being studied for the treatment of asthma.
PF-610,355 has one completed Phase 2 clinical trial, identified as NCT00468975. The study was a blinded trial examining the ability of PF-610,355 to open the airways in asthmatic patients. It enrolled 42 participants in Germany, Sweden, and the United Kingdom.
PF-610,355 is not FDA approved. It is an investigational drug in Phase 2 clinical development for asthma. A Phase 2 trial has been completed, but the drug has not yet received regulatory approval for any indication.